SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is trending due to its strategic partnership with crypto.com/us to launch a U.S. prediction markets platform, alongside plans for sports betting expansion. This news has sparked significant community discussion, with many anticipating a continued rally and potential short squeeze, while others debate its sustainability and the possibility of an offering.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is trending after reporting strong earnings that surpassed expectations and highlighted an accelerating artificial intelligence boom. The company's optimistic outlook, including substantial capital expenditure plans, is sparking widespread confidence across the semiconductor sector and its supply chain partners. Community discussion emphasizes TSM's role as a bellwether, reinforcing the belief in a sustained 'AI megatrend' rather than a short-term bubble.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial Inc (RILY) is trending as the company achieved NASDAQ compliance with its Q3 10-Q filing, showcasing improved financial performance. This development, coupled with a high short interest and numerous in-the-money call options, has ignited community discussions about a potential large short squeeze and significant upward price action, signaling a turnaround from previous challenges.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax (NVAX) is trending due to widespread investor frustration following a perceived "lackluster" management presentation at the JPM conference, which fueled renewed calls for leadership change. Despite strong underlying belief in its Matrix-M platform for oncology and other pipeline potential, the community is actively debating the impact of high short interest and the looming possibility of a proxy fight by Shah Capital to drive shareholder value.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is experiencing strong bullish momentum following a significant analyst upgrade that highlights its server CPUs are reportedly sold out through 2026 due to surging hyperscaler demand for AI. Community discussion centers on this impressive AI accelerator traction and a new strategic partnership with TCS, cementing AMD's position in the rapidly expanding AI chip market. Investors are particularly focused on the company's notable strength and resilience during recent market weakness.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amid reports that Sanofi is preparing a significantly improved takeover offer after the initial $16 per share bid was rejected by the board. The community is buzzing with expectations of a bidding war, with many anticipating a buyout price in the $20-$24 range, underscoring the perceived value of Ocular's assets, particularly ahead of crucial SOL-1 data.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors vigorously debate CEO Ryan Cohen's long-term incentive plan and the company's ongoing business transformation, including store closures. The dedicated retail community continues to rally, expressing frustration with sustained sideways price action while steadfastly anticipating a monumental short squeeze. Community chatter frequently highlights perceived market manipulation by institutional players, fueling calls for accountability and a significant breakout.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund (UUP) is trending as the market actively processes recent Federal Reserve rate adjustments and persistent speculation around future monetary policy. Community discussions are highly polarized, debating potential dollar weakness from ongoing easing against expectations of a significant rally driven by global liquidity demands and central bank divergences.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is rallying sharply amid widespread anticipation of a memory supercycle, driven by tight NAND supply and significant price increases for enterprise SSDs due to surging AI infrastructure demand. The community is fiercely debating whether this remarkable surge, which has pushed the stock to new highs, is sustainable or if it represents an overextended move poised for a correction.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

CAW, or "crow with knife," is trending as its community buzzes about its multichain presence across Solana, BSC, Cronos, and Ethereum (BASE), highlighting its deflationary burn mechanism via Layerzero tech. Enthusiasts are actively promoting the crypto as a "real deal" and a standout meme coin, driven by organic cult-like support. The conversation centers on its technical foundation and potential for growth within the competitive meme coin sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares

Omeros Corporation (NASDAQ:OMER - Get Free Report) CAO David Borges sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an...

Omeros (NASDAQ:OMER) Trading Up 10.3% on Analyst Upgrade

Omeros (NASDAQ:OMER) Stock Price Up 10.3% on Analyst Upgrade...

<ul class="summary-bullets"><li>Investors turned cautious ahead of key U.S. jobs data and a potential court ruling on President Donald Trump’s global tariffs expected Friday.&nbsp;</li><li>Retail traders, however, stayed bullish on SPY and QQQ on Stocktwits.</li></ul>U.S. stock futures were lower early Thursday, following a pullback in major indexes. President&nbsp;Donald Trump’s policy comments triggered a late selloff, with defense, financial, and energy stocks under pressure.Investors are also cautious ahead of the big jobs data and the potential US court&nbsp;ruling on Trump’s global tariffs due on Friday.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq 100 futures were down 0.3%, S&amp;P 500 futures and Dow futures were down 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘bullish’. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has moved back to ‘bullish’ from ‘extremely bullish’ a day ago, amid high message volumes.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Nvidia (NVDA): The Jensen Huang-led chipmaker is reportedly requiring full upfront payment, with&nbsp;no cancellation rights, for H200 chips from Chinese clients to hedge against regulatory export uncertainty. Microsoft (MSFT): The company’s communications&nbsp;chief took to social media to <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-stock-in-focus-as-fresh-layoff-rumors-swirl/cmUGzFNR4PB">blast rumors</a> of fresh mass layoffs as "100% made up," attempting to steady the stock ahead of the&nbsp;market open. Apple (AAPL):&nbsp;Google parent Alphabet (GOOGL) surpassed Apple in market cap for the first time since 2019, closing at $3.888 trillion on Wednesday. It has also switched its banking partner from Goldman Sachs to JPMorgan, the new issuer of the Apple Card.&nbsp; Nio (NIO):&nbsp;The EV maker announced aggressive 2026 expansion plans for Australia, New Zealand, and Thailand, focusing on right-hand-drive markets to bypass Western tariffs. Applied Digital (APLD)&nbsp;saw a high volume of trading following its massive revenue growth report. Ventyx Biosciences (VTYX):&nbsp;Clear Street analyst downgraded the stock to ‘Hold’ from ‘Buy’ with a price target of $14, up from $11, after Eli Lilly (LLY) agreed to acquire Ventyx for $1.2B. Also, LifeSci Capital downgraded it to ‘Market Perform’ from ‘Outperform’ with a $14 price target.&nbsp; Alumis (ALMS) remains on retail radar following a massive ‘follow-on’ financing move following its recent clinical success. Alumis priced an&nbsp;upsized public offering of 17.65 million shares at&nbsp;$17 per share, aiming to raise&nbsp;$300 million. Elevai Labs (ELAB) popped 8%, and&nbsp;Omeros (OMER) rose 5% in after-hours trading on Wednesday, with Omeros gaining steam following a positive FDA conference call on its drug Yartemlea. U.S. defence stocks will be in focus, driven by&nbsp;Trump’s comments to bump up the military budget.Other noteworthy tickers trending on Stocktwits at the time of writing were&nbsp;One Stop Systems (OSS), Paramount Skydance (PSKY), IREN Limited (IREN), Momentus (MNTS), and Regencell Bioscience (RGC).Other Catalysts To Watch On the economic front, investors are looking ahead to the release of Initial Jobless Claims (8:30 a.m. ET), which is a crucial indicator ahead of Friday’s big employment report. Traders will also be monitoring the U.S. Trade Deficit &amp; Productivity data (8:30 a.m. ET) and Consumer Credit data (3 p.m. ET) later today.&nbsp; And noteworthy names on the earnings calendar today include Tilray Brands (TLRY), TD Synnex (SNX),&nbsp;Commercial Metals Company (CMC), and&nbsp;Neogen Corporation (NEOG), among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

Equity

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.


<ul class="summary-bullets"><li>The company set a $36,000 per-vial price for Yartemlea and confirmed the start of its U.S. launch.</li><li>Typical Yartemlea treatment courses use 8–10 vials.</li><li>The U.S. rollout is underway, with initial deliveries expected later this month.</li></ul>Omeros Corp shares rose about 5% in after-hours trading on Wednesday after the company outlined pricing and near-term rollout details for Yartemlea, its newly approved treatment for a rare transplant complication, giving investors clearer visibility into the drug’s early commercial opportunity.<h2 class="st-heading-2">Omeros Puts A Price On Yartemlea</h2>On a special call, Omeros said it has set an initial price of about $36,000 per&nbsp;single-dose&nbsp;vial for Yartemlea, the first and only FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).TA-TMA is a complication after stem cell transplants where damaged small blood vessels cause clotting that can lead to organ failure.The company said that across the trial and the expanded access program, the median utilization was 8–10 vials per treatment course,&nbsp;which would put the total cost at roughly $288,000 to $360,000 per patient.<h2 class="st-heading-2">US Launch Begins&nbsp;</h2>Omeros said it began the U.S. commercial rollout in early January, with its fully hired and trained commercial team now engaging transplant centers nationwide. The company said it is prioritizing high-volume transplant centers, where early utilization is expected to concentrate.The company said that the drug’s product packaging with the FDA-approved label is underway, with transfer to wholesalers targeted for the third week of January and initial deliveries to transplant centers expected shortly thereafter, supported by a next-day delivery model.Omeros added that recent manufacturing campaigns, existing inventory, and a five-year shelf life are expected to provide sufficient supply into late 2029.<h2 class="st-heading-2">FDA Greenlights Yartemlea</h2>Yartemlea&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-omeros-stock-surging-fda-verdict-this-week/cLesvbHREv7">received FDA approval in late December</a>, becoming the first and only therapy indicated for TA-TMA in adults and children aged two years and older. Approval was based on a single-arm pivotal study of 28 patients, supported by data from an expanded access program involving 221 patients.In those studies, patients treated with Yartemlea achieved complete response rates of 61% in the pivotal trial and 68% in evaluable expanded-access patients, with 100-day survival&nbsp;rates of 73% and 74%, respectively. All patients met international criteria for high-risk TA-TMA, a population with historically poor outcomes.Peer-reviewed publications cited by the company showed treatment with Yartemlea was associated with a three to fourfold lower risk of mortality compared to an external control cohort, with one-year survival of about 50% even in previously refractory high-risk patients, compared with earlier survival rates below 20%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Omeros was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/omerss_png_16d6228853.webp" alt="omerss.png" width="971" height="142"><figcaption>OMER sentiment and message volume as of January 7| Source: Stocktwits</figcaption></figure>One user said the move creates an attractive entry point, adding that they remain confident after the special call and expect further upside, citing potential European partnership news, possible analyst upgrades, and an improving bottom-line outlook.<stembedurl>https://stocktwits.com/minnguy64/message/641160269</stembedurl>Another user called the latest development a “stellar” conference call.<stembedurl>https://stocktwits.com/naturegirl669/message/641155439</stembedurl><a href="https://stocktwits.com/symbol/OMER">Omeros’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Omeros Stock Jump 5% In After-Hours Trading Today?

Yartemlea shipments to wholesalers are expected in the third week of January.

Omeros (NASDAQ:OMER) Trading Down 6% - Should You Sell?

Omeros (NASDAQ:OMER) Shares Down 6% - Should You Sell...

Omeros (NASDAQ:OMER) Sets New 12-Month High - Still a Buy?

Omeros (NASDAQ:OMER) Reaches New 12-Month High - Should You Buy...

Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages

Omeros Corporation (NASDAQ:OMER - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings...

Omeros (NASDAQ:OMER) Trading Up 4.6% - Here's Why

Omeros (NASDAQ:OMER) Trading Up 4.6% - Here's Why...

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

Omeros Announces New Date for YARTEMLEA Approval Conference Call

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA (narsoplimab-wuug), the first and only therapy indicated for...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corp